Inhibition of miR-181a promotes midbrain neuronal growth through a Smad1/5-dependent mechanism: implications for Parkinson’s disease

Show simple item record

dc.contributor.author Hegarty, Shane V.
dc.contributor.author Sullivan, Aideen M.
dc.contributor.author O'Keeffe, Gerard W.
dc.date.accessioned 2018-02-20T13:24:13Z
dc.date.available 2018-02-20T13:24:13Z
dc.date.issued 2018
dc.identifier.citation Hegarty, Shane V., Sullivan, Aideen M. and O’Keeffe, Gerard W. (2018) 'Inhibition of miR-181a promotes midbrain neuronal growth through a Smad1/5-dependent mechanism: implications for Parkinson’s disease', Neuronal Signaling, 2(1), NS20170181 (12pp). doi: 10.1042/NS20170181 en
dc.identifier.volume 2
dc.identifier.issued 1
dc.identifier.startpage 1
dc.identifier.endpage 12
dc.identifier.issn 2059-6553
dc.identifier.uri http://hdl.handle.net/10468/5512
dc.identifier.doi 10.1042/NS20170181
dc.description.abstract Parkinson’s disease (PD) is the second most common neurodegenerative disease, and is characterized by the progressive degeneration of nigrostriatal dopaminergic (DA) neurons. Current PD treatments are symptomatic, wear off over time and do not protect against DA neuronal loss. Finding a way to re-grow midbrain DA (mDA) neurons is a promising disease-modifying therapeutic strategy for PD. However, reliable biomarkers are required to allow such growth-promoting approaches to be applied early in the disease progression. miR-181a has been shown to be dysregulated in PD patients, and has been identified as a potential biomarker for PD. Despite studies demonstrating the enrichment of miR-181a in the brain, specifically in neurites of postmitotic neurons, the role of miR-181a in mDA neurons remains unknown. Herein, we used cell culture models of human mDA neurons to investigate a potential role for miR-181a in mDA neurons. We used a bioninformatics analysis to identify that miR-181a targets components of the bone morphogenetic protein (BMP) signalling pathway, including the transcription factors Smad1 and Smad5, which we find are expressed by rat mDA neurons and are required for BMP-induced neurite growth. We also found that inhibition of neuronal miR-181a, resulted in increased Smad signalling, and induced neurite growth in SH-SY5Y cells. Finally, using embryonic rat cultures, we demonstrated that miR-181a inhibition induces ventral midbrain (VM) and cortical neuronal growth. These data describe a new role for miR-181a in mDA neurons, and provide proof of principle that miR-181a dysresgulation in PD may alter the activation state of signalling pathways important for neuronal growth in neurons affected in PD. en
dc.description.sponsorship Irish Research Council (R15897); National University of Ireland (R16189) en
dc.format.mimetype application/pdf en
dc.language.iso en en
dc.publisher Portland Press en
dc.relation.uri http://www.neuronalsignaling.org/content/2/1/NS20170181
dc.rights ©2018, the Author(s) This is an Accepted Manuscript; not the final Version of Record. You are encouraged to use the final Version of Record that, when published, will replace this manuscript and be freely available under a Creative Commons licence. en
dc.rights.uri https://creativecommons.org/licenses/by/4.0/
dc.subject Axon en
dc.subject Dopaminemicro en
dc.subject RNA en
dc.title Inhibition of miR-181a promotes midbrain neuronal growth through a Smad1/5-dependent mechanism: implications for Parkinson’s disease en
dc.type Article (peer-reviewed) en
dc.internal.authorcontactother Gerard O'Keeffe, Anatomy & Neuroscience, University College Cork, Cork, Ireland. +353-21-490-3000 Email: g.okeeffe@ucc.ie en
dc.internal.availability Full text available en
dc.description.version Published Version en
dc.contributor.funder National University of Ireland
dc.contributor.funder Irish Research Council
dc.contributor.funder Science Foundation Ireland
dc.description.status Peer reviewed en
dc.identifier.journaltitle Neuronal Signaling en
dc.internal.IRISemailaddress g.okeeffe@ucc.ie en
dc.identifier.articleid NS20170181
dc.relation.project info:eu-repo/grantAgreement/SFI/SFI Career Development Award/15/CDA/3498/IE/Development of GDF5 neurotrophic factor therapy for Parkinson_s disease./


Files in this item

This item appears in the following Collection(s)

Show simple item record

©2018, the Author(s) This is an Accepted Manuscript; not the final Version of Record. You are encouraged to use the final Version of Record that, when published, will replace this manuscript and be freely available under a Creative Commons licence. Except where otherwise noted, this item's license is described as ©2018, the Author(s) This is an Accepted Manuscript; not the final Version of Record. You are encouraged to use the final Version of Record that, when published, will replace this manuscript and be freely available under a Creative Commons licence.
This website uses cookies. By using this website, you consent to the use of cookies in accordance with the UCC Privacy and Cookies Statement. For more information about cookies and how you can disable them, visit our Privacy and Cookies statement